The agency first approved Victoza to treat patients with type 2 diabetes in 2010. The drug may now be used to reduce the risk of cardiovascular events — like heart attacks and strokes — in this patient population.
The expanded approval stems from a clinical trial, which showed Victoza reduced the risk of cardiovascular events by 13 percent compared to a placebo.
More articles on supply chain:
7 drugmakers in the headlines
Gilead to acquire Kite Pharma for nearly $12B: 4 things to know
Blood supplier expects shortages in Texas amid Hurricane Harvey
